PTC Therapeutics, Inc. Unrealized Gain (Loss) on Investments
PTC Therapeutics, Inc. (PTCT) reported Unrealized Gain (Loss) on Investments of $852.00 thousand for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-10-29.
Discontinued › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnInvestments · last filed 2020-10-29
- PTC Therapeutics, Inc. unrealized gain (loss) on investments for the quarter ending 2020-09-30 was $2.45M, a 2.17% increase year-over-year.
- PTC Therapeutics, Inc. unrealized gain (loss) on investments for the quarter ending 2020-06-30 was -$26.00K, a 120.16% decline year-over-year.
- PTC Therapeutics, Inc. unrealized gain (loss) on investments for the quarter ending 2020-03-31 was -$1.57M.
- PTC Therapeutics, Inc. unrealized gain (loss) on investments for the quarter ending 2019-12-31 was -$335.00K.
- PTC Therapeutics, Inc. unrealized gain (loss) on investments for fiscal 2019 was $2.19M.
- PTC Therapeutics, Inc. unrealized gain (loss) on investments for fiscal 2018 was $0.00.
- PTC Therapeutics, Inc. unrealized gain (loss) on investments for fiscal 2017 was $0.00.
| Period end | Unrealized Gain (Loss) on Investments 3 month | Unrealized Gain (Loss) on Investments 6 month | Unrealized Gain (Loss) on Investments 9 month | Unrealized Gain (Loss) on Investments 12 month |
|---|---|---|---|---|
| 2020-09-30 | $2.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $2.43M derived: sum of 2 quarters · filed 2020-10-29 | $852.00K 10-Q · filed 2020-10-29 | $517.00K derived: sum of 4 quarters · filed 2020-10-29 |
| 2020-06-30 | -$26.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | -$1.60M 10-Q · filed 2020-08-05 | -$1.94M derived: sum of 3 quarters · filed 2020-08-05 | $465.00K derived: sum of 4 quarters · filed 2020-10-29 |
| 2020-03-31 | -$1.57M 10-Q · filed 2020-04-30 | -$1.91M derived: sum of 2 quarters · filed 2020-04-30 | $491.00K derived: sum of 3 quarters · filed 2020-10-29 | $620.00K derived: sum of 4 quarters · filed 2020-10-29 |
| 2019-12-31 | -$335.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $2.06M derived: sum of 2 quarters · filed 2020-10-29 | $2.19M derived: sum of 3 quarters · filed 2020-10-29 | $2.19M 10-K · filed 2020-03-02 |
| 2019-09-30 | $2.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $2.53M derived: sum of 2 quarters · filed 2020-10-29 | $2.53M 10-Q · filed 2020-10-29 | $2.53M derived: sum of 4 quarters · filed 2020-10-29 |
| 2019-06-30 | $129.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $129.00K 10-Q · filed 2020-08-05 | $129.00K derived: sum of 3 quarters · filed 2020-08-05 | $129.00K derived: sum of 4 quarters · filed 2020-08-05 |
| 2019-03-31 | $0.00 10-Q · filed 2020-04-30 | $0.00 derived: sum of 2 quarters · filed 2020-04-30 | $0.00 derived: sum of 3 quarters · filed 2020-04-30 | |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $0.00 derived: sum of 2 quarters · filed 2020-03-02 | $0.00 10-K · filed 2020-03-02 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | $0.00 10-Q · filed 2019-10-30 | ||
| 2018-06-30 | $0.00 10-Q · filed 2019-08-06 | |||
| 2017-12-31 | $0.00 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |